Posters

Comparison of short-term results of ranibizumab to dexametasone implant in treatment of naive diabetic macular edema patients

Poster Details

First Author: B.Erden TURKEY

Co Author(s):    S. Bolukbasi   S. Erdenoz   A. Cakir   M. Elcioglu                    

Abstract Details



Purpose:

To compare the short-term results of dexamethasone (Dex) implant with those of three consequtive ranibizumab injections in treatment of naive diabetic macular edema patients.

Setting:

Okmeydani Education and Research Hospital, Istanbul, Turkey

Methods:

In this retrospective study, 37 eyes of 34 diabetic macular edema patients were enrolled into the ranibizumab (R) group; 33 eyes of 30 patients were enrolled in the Dex (D) group. Both groups were treatment naive. The R group was treated with 3 consequtive monthly ranibizumab injections; the D group was injected only one Dex implant. Both groups underwent pre-injection, postinjection at 1st month, 2nd month and 4th month optic coherence tomography (OCT) exams. Best corrected visual acuity (BCVA; Snellen), biomicroscopy, fundoscopy and intraocular pressure (IOP) were recorded at each visit. Data were analysed with SPSS 11.0 statistically.

Results:

Mean age (R: 62.4; D:64.2), duration of diabetes (R:8.9 vs D: 9.3 years) and pre-treatment central macular thickness (CMT; R:423; D: 452) were statistically indifferent. The IOP changes were within and between both groups (R: 16.5,15.6, 16.2,15.4 mmHg vs D: 15.5,16.9,17.6,16.3 mmHg) insignificant. The BCVA increased in R group from 0.28 lines to 0.38; 0.42 and 0.49 (p<0.05); in D group from 0.18 to 0.29; 0.37 and 0.37 at final visit (p<0.05) . The comparison of visual gain at 4th month visit showed no difference (R: 0.21; D:0.19; p>0.05). The CMT decreased in R group from 423µ to 355µ, 344µ and to 313µ (p<0.05); in D group from 452µ to 313µ, 303µ and to 307µ (p<0.05). Although the comparison of CMT reduction between both groups at 1st and 2nd month visits revealed significant difference in favor of D group (139µ vs 68.5µ p<0.01 at 1th month; 149µ vs 78.9µ at 2th month p<0.01); the final CMT reduction in both groups was statistically insignificant (145µ vs 110.5µ p>0.05). In D group; 3 eyes (9%) had to be treated with topical anti-glaucomatous agents in the follow-up.

Conclusions:

Both monthly ranibizumab injections and dexametasone implant are equally effective in short-term treatment of diabetic macular edema. Although the treatment effect of Dex implant was seen earlier in the follow-up, the elevation of IOP may be a clinical concern in some cases.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy